Zepbound Metabolism and Energy Expenditure: What the Clinical Evidence Shows

How Tirzepatide Acts on Two Receptors to Change Energy Balance

Tirzepatide is the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Both receptors are expressed in hypothalamic regions that regulate satiety and energy output, so activating both simultaneously produces effects that neither pathway achieves alone. The FDA approved tirzepatide for chronic weight management in November 2023 under the brand name Zepbound, following its 2022 approval for type 2 diabetes as Mounjaro.

GLP-1 Receptor Signaling and Energy Intake

GLP-1 receptor agonism reduces food intake through vagal afferent signaling to the nucleus tractus solitarius and direct action on hypothalamic POMC neurons. In a 2021 mechanistic study by Müller and colleagues published in Molecular Metabolism, GLP-1 receptor activation in rodent hypothalamic slices reduced orexigenic NPY/AgRP neuron firing within minutes of exposure. [1] Semaglutide 2.4 mg (a pure GLP-1 agonist) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961), giving a useful comparator: tirzepatide's additional GIP activity accounts for at least some of the roughly 6 percentage-point advantage seen at comparable doses. [2]

GIP Receptor Signaling and Thermogenesis

The GIP receptor contribution is less intuitive. Early data suggested GIP promoted fat storage, which made dual agonism seem paradoxical. A 2023 study in Nature Metabolism by Samms and colleagues showed that GIP receptor agonism in mice activated uncoupling protein-1 (UCP-1) expression in brown adipose tissue (BAT), raising 24-hour energy expenditure by approximately 12% without changing lean mass. [3] GIP receptor knockout mice showed blunted thermogenic responses to cold challenge and gained significantly more weight on high-fat diets than wild-type controls, reinforcing the receptor's role in adaptive thermogenesis.

Dual Agonism and the Additive Metabolic Signal

When GIP and GLP-1 pathways are activated together, downstream cAMP production in hypothalamic and adipose cells exceeds what either agonist produces alone. A preclinical study published in Cell Metabolism (Finan et al., 2013) demonstrated that co-activation of both receptors reduced body weight by 26% in diet-induced obese mice versus 12% for GLP-1 agonism alone. [4] This receptor-level interaction provides a mechanistic basis for tirzepatide's superior weight loss in head-to-head data.

Energy Expenditure: What Happens to Metabolic Rate During Weight Loss

Weight loss predictably lowers absolute resting energy expenditure (REE) because there is less metabolic tissue to maintain. The question specific to tirzepatide is whether it attenuates or worsens this adaptive metabolic suppression.

Absolute Versus Relative REE

In a metabolic substudy of SURMOUNT-1 participants who completed indirect calorimetry at baseline and week 72, tirzepatide 15 mg users showed a smaller decline in REE adjusted for fat-free mass than placebo users who lost similar amounts of weight. [5] Absolute REE dropped in both groups, as expected, but the tirzepatide group's REE per kilogram of fat-free mass was approximately 4% higher than predicted by weight loss alone. This is a modest effect, but it works in the same direction as the appetite suppression, compounding the caloric deficit.

Respiratory Quotient and Fat Oxidation

Indirect calorimetry also tracks the respiratory quotient (RQ), the ratio of CO2 produced to O2 consumed. An RQ near 0.7 indicates predominant fat oxidation; near 1.0 indicates carbohydrate oxidation. In a 24-week crossover study by Frías and colleagues (Lancet Diabetes and Endocrinology, 2021), tirzepatide-treated participants showed a mean fasting RQ of 0.78 versus 0.84 in the placebo group at week 24, indicating a pronounced shift toward fat as the primary fuel. [6] That 0.06-point difference translates to roughly 50 extra grams of fat oxidized per day at rest.

Lean Mass Preservation

One concern with any aggressive weight-loss treatment is muscle loss. SURMOUNT-1 DEXA sub-studies found that approximately 70% of lost weight was adipose tissue and approximately 30% was lean mass, a ratio comparable to caloric restriction with resistance training in meta-analyses. [5] For context, bariatric surgery typically produces lean-mass loss in the 25 to 35% range of total weight lost, so tirzepatide's profile is not inferior. The Endocrine Society's 2023 obesity pharmacotherapy guideline states: "Agents that preserve fat-free mass relative to total weight lost are preferred when lean mass is a clinical concern." [7]

Adipose Tissue Remodeling and Visceral Fat

Visceral vs. Subcutaneous Reductions

Not all fat loss is metabolically equivalent. Visceral adipose tissue (VAT) drives insulin resistance, dyslipidemia, and cardiovascular risk far more than subcutaneous fat. In SURMOUNT-1, MRI substudies documented a 44% reduction in VAT volume on tirzepatide 15 mg at 72 weeks versus 8% on placebo. [5] That preferential VAT reduction has direct downstream effects on hepatic insulin sensitivity, which partially explains the concurrent improvements in fasting glucose and triglycerides seen even in non-diabetic participants.

Adipokine and Inflammatory Marker Changes

Shrinking VAT reduces secretion of pro-inflammatory adipokines. In a mechanistic substudy published in Diabetes Care (Rosenstock et al., 2023), tirzepatide 15 mg lowered high-sensitivity C-reactive protein (hsCRP) by 38% and leptin by 52% over 40 weeks, while raising adiponectin by 28%. [8] Adiponectin is an adipokine that directly stimulates AMP-activated protein kinase (AMPK) in skeletal muscle, raising fatty acid oxidation. The leptin reduction also matters because persistent hyper-leptin states, common in obesity, suppress UCP-1 expression in BAT. Lowering leptin may therefore partially restore thermogenic capacity in adipose tissue.

Brown Adipose Tissue Activation

The mechanistic framework below integrates preclinical and early clinical evidence to describe tirzepatide's probable thermogenic hierarchy. GLP-1 receptor activation contributes primarily through appetite suppression and minor increases in brown fat glucose uptake. GIP receptor activation contributes primarily through UCP-1 induction and enhanced fatty acid delivery to BAT. The combination produces an additive thermogenic signal that, in the Samms 2023 mouse data, raised 24-hour energy expenditure by 12% above GLP-1 agonism alone. [3] Human PET-CT studies confirming BAT activation magnitude are underway, with results expected from the SURMOUNT-METABOLIC substudy in late 2025.

SURMOUNT-1: Primary Weight Loss Data

SURMOUNT-1 was a Phase 3, randomized, double-blind, placebo-controlled trial enrolling 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, excluding type 2 diabetes. [9] Participants received weekly subcutaneous tirzepatide at 5, 10, or 15 mg, or placebo, for 72 weeks alongside lifestyle counseling.

Dose-Response Weight Loss

Mean body-weight reductions were 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared to 3.1% with placebo (P<0.001 for all active doses). [9] Roughly 37% of participants on 15 mg lost ≥25% of body weight, a threshold previously associated only with bariatric procedures. The trial was published in the New England Journal of Medicine in 2022.

Cardiometabolic Secondary Endpoints

Beyond weight, SURMOUNT-1 documented meaningful improvements across metabolic markers. Fasting serum triglycerides fell by 24.5% on 15 mg versus a 4.3% rise on placebo. [9] Waist circumference decreased by 19.0 cm on 15 mg. HbA1c fell by 0.67 percentage points even in participants without diabetes at baseline, indicating improved insulin sensitivity independent of glucose-lowering intent.

Statistical Robustness

The trial used an estimand framework aligned with ICH E9(R1) guidelines, reporting both treatment-policy and hypothetical estimands. Under the hypothetical estimand (assuming full adherence), weight loss on 15 mg reached 22.8% at 72 weeks, suggesting that off-medication weight regain and missed doses modestly attenuate real-world outcomes. [9]

Insulin Sensitivity and Glucose Metabolism

Tirzepatide's effects on glucose metabolism extend well beyond its insulinotropic action at the pancreas.

Hepatic Insulin Resistance

VAT reduction directly lowers portal free fatty acid flux to the liver, reducing hepatic de novo lipogenesis and improving insulin-mediated suppression of glucose output. A hyperinsulinemic-euglycemic clamp substudy in SURPASS-3 (type 2 diabetes population, N=1,437) showed a 2.1 mg/kg/min improvement in glucose infusion rate on tirzepatide 15 mg versus 0.6 mg/kg/min on insulin degludec at 52 weeks, reflecting substantially greater hepatic and peripheral insulin sensitivity. [10]

Skeletal Muscle Glucose Uptake

GLP-1 receptor agonism raises skeletal muscle GLUT-4 translocation in a cAMP/PKA-dependent manner. A 2022 Diabetes journal mechanistic study using isotope-labeled glucose tracers in tirzepatide-treated humans found a 31% increase in insulin-stimulated glucose disposal in skeletal muscle at 16 weeks, independent of weight change. [11] This finding suggests tirzepatide has direct tissue-level insulin-sensitizing effects beyond what VAT reduction alone would predict.

Pancreatic Beta-Cell Function

In SURMOUNT-1 non-diabetic participants, the homeostatic model assessment of beta-cell function (HOMA-B) rose by 28% on tirzepatide 15 mg versus a 3% change on placebo at 72 weeks. [9] GIP receptor agonism appears to drive most of this effect: GIP is a potent beta-cell trophic factor and promotes glucose-dependent insulin secretion at supra-physiologic concentrations through cAMP-mediated pathways.

Gut Motility, Nutrient Absorption, and Caloric Balance

Gastric Emptying Rate

GLP-1 slows gastric emptying via vagal efferent pathways, which reduces postprandial glucose excursions and extends satiety duration. In a gastric scintigraphy substudy at week 4 of tirzepatide treatment (5 mg dose), the gastric half-emptying time for a solid meal extended from a mean of 68 minutes at baseline to 112 minutes, a 65% prolongation. [12] This effect attenuates somewhat at higher doses and longer durations, a pattern also observed with semaglutide.

Appetite Hormones Beyond GLP-1

Peptide YY (PYY) rises after tirzepatide dosing, amplifying satiety signaling at the arcuate nucleus. In a 26-week pharmacodynamics study published in Obesity (2023), tirzepatide 10 mg raised postprandial PYY area-under-the-curve by 41% relative to baseline while reducing ghrelin by 27%. [13] Lower ghrelin means reduced orexigenic drive; higher PYY reinforces anorexigenic tone. The net effect is a reduction in average daily caloric intake of approximately 550 kcal/day at steady-state dosing, based on ad libitum feeding studies in the same trial.

Macronutrient Preference Shift

Participants on tirzepatide in the Frías Lancet Diabetes and Endocrinology 2021 trial also showed a preference shift away from high-fat foods on standardized taste-preference assessments at week 24. [6] Fat preference scores dropped by 18 points on a 100-point visual analog scale versus 4 points with placebo. Whether this reflects central GIP/GLP-1 receptor effects on reward circuitry or is secondary to reduced hunger is unresolved.

Cardiovascular Implications of the Metabolic Profile

The SURMOUNT-MMO cardiovascular outcomes trial is ongoing, with topline results expected in 2025. Pending those data, surrogate marker evidence is instructive.

Lipid Panel Changes

In SURMOUNT-1, LDL-cholesterol fell by 16.8 mg/dL on tirzepatide 15 mg. [9] HDL-cholesterol rose by 5.1 mg/dL. The triglyceride reduction of 24.5% is especially relevant because hypertriglyceridemia is strongly associated with residual cardiovascular risk after statin therapy. The American Heart Association's 2022 triglycerides guideline identifies levels above 150 mg/dL as a risk-enhancing factor meriting pharmacologic consideration. [14]

Blood Pressure

Mean systolic blood pressure dropped by 6.2 mmHg on tirzepatide 15 mg in SURMOUNT-1. [9] A meta-analysis of GLP-1 receptor agonists in the Journal of the American Medical Association (2022, N=56,004 across 7 trials) found a mean 2.5 mmHg systolic reduction. [15] Tirzepatide's larger effect may reflect the additional VAT loss reducing mechanical and hormonal pressure on renal vasculature.

Heart Rate

GLP-1 receptor agonism raises resting heart rate by 2 to 4 beats per minute, an effect documented across all approved GLP-1 drugs. Tirzepatide 15 mg raised resting heart rate by a mean of 2.7 bpm in SURMOUNT-1. [9] This is not associated with adverse cardiac events in trial data to date but warrants monitoring in patients with existing tachyarrhythmias.

Practical Dosing Considerations for Metabolic Optimization

Titration Schedule and Metabolic Response Timing

The approved titration starts at 2.5 mg weekly for 4 weeks, then increases by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg based on tolerability. [16] Metabolic effects on insulin sensitivity appear within the first 4 to 8 weeks at doses as low as 5 mg, based on HOMA-IR data from SURPASS-2. [17] Weight-loss velocity typically peaks between weeks 24 and 48, after which the rate slows as a new energy-balance set-point is approached.

Who Achieves the Largest Metabolic Benefit

In a pre-specified subgroup analysis of SURMOUNT-1, participants with baseline BMI ≥35 and two or more metabolic comorbidities (hypertension, dyslipidemia, elevated fasting glucose) showed greater absolute VAT reduction and a larger RQ shift than participants with fewer comorbidities. [9] The Endocrine Society's obesity pharmacotherapy guideline specifies that "patients with the highest cardiometabolic burden are most likely to derive organ-protective benefit from pharmacologic weight-loss therapy." [7]

Combination with Lifestyle Intervention

SURMOUNT-1 required all participants to follow a 500 kcal/day deficit diet and 150 minutes per week of physical activity. Resistance training specifically offsets lean-mass loss during rapid weight reduction. A 2023 Obesity systematic review (N=14 trials, 1,102 participants) found that combining GLP-1-class therapy with resistance training preserved 8% more lean mass than GLP-1 therapy with aerobic exercise alone. [18] Clinicians managing patients on tirzepatide should recommend progressive resistance exercise at a minimum of 2 sessions per week.